Overall Highlights

• The U.S. and China are experiencing heightened tensions over trade and military issues, particularly regarding Taiwan.
• Both nations are engaging in strategic posturing, with the U.S. enhancing its military capabilities in the region and China warning against European trade restrictions.
• Trade negotiations continue amid conflicting narratives, with the U.S. pushing for stricter measures against China and China criticizing these actions as aggressive.
• Taiwan’s military spending reflects concerns over potential Chinese aggression, while China emphasizes the importance of cross-strait trade despite political friction.
• The global tech landscape remains impacted by U.S.-China relations, particularly in the semiconductor sector.

United States Perspective (United States Sources)

• The U.S. is focused on strengthening trade agreements and countering China’s influence in Europe and Asia.
• Recent articles highlight U.S. military preparations in response to potential threats from China, particularly regarding Taiwan.
• The U.S. government has ruled out collaboration with China on AI safety, indicating a hardening stance against Chinese tech advancements.

China Perspective (China Sources)

• China criticizes U.S. actions as aggressive and detrimental to global trade, particularly regarding proposed European tariffs.
• Chinese sources emphasize the need for normalization of relations with Japan amid tensions over Taiwan, reflecting broader regional concerns.
• China warns that U.S. military expansions could escalate tensions in the Taiwan Strait, while also highlighting the resilience of cross-strait trade despite political challenges.

Sources

This summary is based on 20 articles from the following sources:

1. [en-US] Get the facts from trade expert after U.S.-China trade deal - wdsu.com (9/30/2026)
2. [en-US] Xi’s narrative of WWII obscures the ROC’s role - Taipei Times (9/30/2026)
3. [en-US] Beijing criticises push for European Section 301-style tool to counter China - South China Morning Post (9/30/2026)
4. [en-US] Beijing warns of retaliation if Europe imposes curbs on Chinese businesses - CNBC (9/30/2026)
5. [en-US] China Warns Broad EU Tariffs Could Disrupt Trade Negotiations - Bloomberg.com (9/30/2026)
6. [en-US] Less than a week after Chinese President Xi Jinping’s visit, the US government rules out working with Chi - The Times of India (9/30/2026)
7. [en-US] Taiwan plans US$850 million munition spend to prepare for potential PLA blockade - South China Morning Post (9/30/2026)
8. [en-US] China bans online financial promos by private brokers to stop loan misuse - South China Morning Post (9/30/2026)
9. [en-US] China-Taiwan cross-strait trade defies political friction - Asia News Network (9/30/2026)
10. [en-US] China Says Japan Ties Need ‘Normalization’ Again Over Taiwan Row - Bloomberg.com (9/30/2026)
11. [en-US] Cheap and illegal: mainlanders post social media adverts for services in Hong Kong - South China Morning Post (9/30/2026)
12. [en-US] Trump rejects calls to work with China on AI safety despite Xi summit progress - South China Morning Post (9/29/2026)
13. [en-US] Eiffel Tower chief out over removal of women staff for Hindu group’s visit - South China Morning Post (9/29/2026)
14. [en-US] US Navy launches drone command that could reshape Taiwan war planning - South China Morning Post (9/29/2026)
15. [en-US] Nvidia, AMD CEOs join Tsinghua advisory board as US-China chip tensions persist - South China Morning Post (9/29/2026)
16. [en-US] Sell family jewels for latest iPhone? In India, craze dials up debate - South China Morning Post (9/29/2026)
17. [en-US] Opinion | What trap? US-China relations show conflict is far from inevitable - South China Morning Post (9/29/2026)
18. [en-US] To manage AI threats, US and China ‘need to get on the same page’ on risks - South China Morning Post (9/29/2026)
19. [en-US] India-Europe trade corridor gets Trump’s backing, but can it survive war? - South China Morning Post (9/29/2026)
20. [en-US] AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech - South China Morning Post (9/29/2026)